Brinker Capital Investments’s NovoCure NVCR Stock Holding History

Brinker Capital Investments’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-10,606	Closed	-$778K	–	1627
2022 Q4	$778K	Buy	10,606 +333	+3%	+$25.1K	0.02%	818
2022 Q3	$781K	Buy	10,273 +868	+9%	+$67.7K	0.02%	796
2022 Q2	$654K	Sell	9,405 -507	-5%	-$38.2K	0.01%	878
2022 Q1	$821K	Sell	9,912 -1,248	-11%	-$91.9K	0.01%	873
2021 Q4	$838K	Sell	11,160 -414	-4%	-$41.6K	0.01%	886
2021 Q3	$2.57M	Hold	11,574	–	–	0.04%	470
2021 Q2	$2.57M	Buy	11,574 +1,084	+10%	+$211K	0.03%	526
2021 Q1	$1.39M	Sell	10,490 -10,402	-50%	-$1.65M	0.02%	608
2020 Q4	$3.62M	Buy	20,892 +10,186	+95%	+$1.39M	0.06%	403
2020 Q3	$1.19M	Buy	+10,706	New	+$856K	0.02%	632
2020 Q1	–	Sell	-54	Closed	-$5K	–	599
2019 Q4	$5K	Buy	+54	New	+$4.36K	﹤0.01%	661

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

Brinker Capital Investments's NVCR Position: Q1 2023 in Review

Brinker Capital Investments sold out of NovoCure (NVCR) in Q1 2023, closing a stake of 10,606 shares — an estimated $778K sold.

Brinker Capital Investments first reported a position in NVCR in Q4 2019 and held it in 11 quarters. The position peaked at $3.62M in Q4 2020. 295 funds tracked by Wall St. Rank hold NVCR as of Q1 2023.

Brinker Capital Investments reported no remaining NovoCure position as of Q1 2023 after selling out during the quarter.
Brinker Capital Investments sold 10,606 NovoCure shares in Q1 2023, an estimated $778K.
Brinker Capital Investments first reported a position in NovoCure in Q4 2019 and held it in 11 quarters.
Brinker Capital Investments's NovoCure position peaked at $3.62M in Q4 2020.
295 funds tracked by Wall St. Rank held NovoCure as of Q1 2023.

Based on Brinker Capital Investments's 13F filing for Q1 2023, filed 31 Jul 2025.